New Orleans-Two phase III trials, one phase II trial, and one extension trial are under way for anti-VEGF agent, ranibizumab (Lucentis, Genentech). The extension trial indicates that ranibizumab provides a long-term benefit to patients and that it is well tolerated, according to Jeffrey S. Heier, MD, who described the studies during the retina subspecialty day here at the American Academy of Ophthalmology annual meeting.
Irvine, CA-For years, Roger F. Steinert, MD, struggled to carve out time to explore his theories while tending to patients and teaching students in Boston.
Santa Barbara, CA-Miravant Medical Technologies will launch an additional clinical trial in an effort to meet the FDA's conditions for final marketing approval of its tin ethyl etiopurpurin (SnET2).
Plymouth Meeting, PA-Genaera Corp. is expanding its third U.S. phase II clinical trial of squalamine, its small-molecule, anti-angiogenic drug for the treatment of wet age-related macular degeneration (AMD).
An implantable miniature telescope (IMT, VisionCare Ophthalmic Technologies Inc.) may help improve visual acuity in patients with bilateral, end-stage macular degeneration, according to the phase II/III results at 6 months.
Eyeonics announces that it has received FDA approval to market its accommodating IOL (Crystalens) in 0.25-D steps.
Two phase III trials, one phase II trial, and one extension trial of anti-VEGF agent Lucentis (Genentech) are under way.
The C-01-99 phase III clinical trial, which compared a 15-mg dose of anecortave acetate (Alcon Laboratories) with standard administration of verteporfin for the treatment of neovascular age-related macular degeneration (AMD), found that there was no statistical difference between the two treatments.
The VEGF (vascular endothelial growth factor) Inhibition Study in Ocular Neovascularization (VISION), a phase III appraisal of three doses of pegaptanib sodium injection (Macugen, Eyetech Pharmaceuticals) (0.3, 1, and 3 mg) compared with a sham procedure, found that the 0.3-mg dose of Macugen improves visual outcomes in patients with age-related macular degeneration.
Kingston, PA-FDA study results show the safety and effectiveness of the investigational viscous-dispersive ophthalmic viscosurgical device (OVD) DisCoVisc (Alcon Laboratories) for use during cataract surgery and IOL implantation, said Harvey Reiser, MD.
With the relatively recent FDA approval of capsular tension rings (CTRs), cataract surgeons finally have the opportunity to use these devices for their patients
Therapies for the management of age-related macular degeneration (AMD) have progressed rapidly in recent years. Ophthalmology Times convened a panel of cutting-edge retinal specialists from across the United States to discuss the latest in the diagnosis of AMD and to explore current practice patterns with pharmaceutical and surgical treatment options.
The FDA approval in mid-September of the Verisyse/Artisan phakic IOL [Advanced Medical Optics Inc. (AMO) and Ophtec USA] for use in patients with myopia could be the start of a revolution comparable to the advent of LASIK, according to Eric D. Donnenfeld, MD, FACS, one of the investigators who took part in clinical trials of the lens.
San Diego-The Artisan Hyperopia IOL (Ophtec BV) appears to be safe, effective, and stable for the treatment of high and extreme hyperopia, according to Edward E. Manche, MD, who reported the interim results of the FDA phase III clinical trial at the American Society of Cataract and Refractive Surgery annual meeting.
VisiJet Inc. has received FDA approval for its EpiLift System, an ophthalmic surgical device designed for separating corneal tissue.
The U.S. FDA has granted WaveLight Laser Technologie AG, an investigational device exemption that allows the company, based in Erlangen, Germany, to conduct additional clinical studies in the United States for its Allegretto Wave excimer laser system.
Atlanta -Start-up ophthalmic pharmaceutical developer Alimera Sciences Inc. has launched its first product, a multi-dose, emollient-based artificial tear drop.
Fort Lauderdale, FL-Intravenous squalamine lactate being developed by Geneara Corp. shows promise as a safe and effective treatment for choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), according toresults of a phase I/II trial presented by Charles A. Garcia, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
San Diego-The Artisan/Verisyse phakic IOL (Ophtec USA, AMO) fared well in preliminary analysis of data from one U.S. investigational center. It appears to be a safeand effective implant for use in patients with high myopia, according to Kerry Assil, MD, who spoke during the American Society of Cataract and Refractive Surgery annual meeting.
Photodynamic therapy with verteporfin is the most promising of the FDA-approved therapies for exudative CNV.
San Diego-Regression after refractive surgery may be reduced by using ultraviolet A (UVA) cross-linking techniques to stabilize the cornea. The preliminary results of UVA cross-linking after refractive procedures demonstrated that regression stopped in the near term and appeared to be without adverse effects.
Pre-formed gel masks are applied to patients requesting injectable cosmetic therapies.
Dallas-Refocus Group Inc., a medical device company engaged in the research and development of treatments for eye disorders, announced promising preliminary data from the company's ongoing phase II clinical trials for the treatment of presbyopia.
Understanding of chronic dry eye has come a long way in recent years. The treatment spectrum has expanded and ophthalmologists now have a range of therapeutic options.
Rockville Center, NY-Nedocromil sodium is the mainstay of therapy for patients who need chronic medication because it offers continued relief without the development of tolerance.
